NMRA FY 2024 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$263M

Net Income

-$244M

EPS (Diluted)

$-1.53

Cash Flow

Operating Cash Flow

-$183M

Free Cash Flow

-$183M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$317M

Total Liabilities

$30M

Stockholders' Equity

$287M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$668,000	+100.0%
Operating Income	-$263M	-$188M	-40.0%
Net Income	-$244M	-$236M	-3.3%